Samsung Biologics announced the launch of its in-house master cell bank (MCB) production and vector construction services, significantly bolstering its contract development organization (CDO) capabilities and accelerating drug development timelines for its clients.
The announcement follows a webinar held on March 19, titled “Accelerating Vector Construction-to-IND: Achieving a 9-Month Timeline Through Integrated Cell Line Development,” where the company detailed the new services.
By bringing these critical processes in-house, previously outsourced to external partners, Samsung Biologics aims to minimize the need for transferring valuable drug candidates and sensitive data to third-party vendors. This strategic move is projected to streamline development timelines, enhance data consistency, and provide enhanced intellectual property protection for its clients.
The company also highlighted its optimized development framework, enabling completion of the process from vector construction to Investigational New Drug (IND) submission within an impressive nine-month timeframe. This expedited timeline is a key component of Samsung Biologics’ comprehensive end-to-end service strategy.
Master cell bank production and vector construction are crucial steps in the manufacturing of antibody therapeutics. Vectors function as gene delivery systems, effectively inserting the genetic instructions necessary for antibody production into cells. Master cell banks are meticulously created by selecting and scaling high-quality cells under stringent Good Manufacturing Practice (GMP) standards.
“By internalizing cell line development services, we aim to become a faster and more reliable partner in our clients’ drug development journey,” stated Lee Sang-myung, Vice President in charge of CDO development at Samsung Biologics. “We will continue to expand our technologies and service offerings to deliver tailored solutions that meet the evolving needs of our clients.”
jwjeon7625
